Bariatric surgery as potential treatment for nonalcoholic fatty liver disease: a future treatment by choice or by chance?

Shuja Hafeez, Mohamed H Ahmed, Shuja Hafeez, Mohamed H Ahmed

Abstract

Morbid obesity is strongly associated with nonalcoholic fatty liver disease (NAFLD) which is one of the most common causes of chronic liver disease worldwide. The current best treatment of NAFLD and NASH is weight reduction through life style modifications, antiobesity medication, and bariatric surgery. Importantly, bariatric surgery is the best alternative option for weight reduction if lifestyle modifications and pharmacological therapy have not yielded long-term success. Bariatric surgery is an effective treatment option for individuals who are grossly obese and associated with marked decrease in obesity-related morbidity and mortality. The most common performed bariatric surgery is Roux-en-Y gastric bypass (RYGB). The current evidence suggests that bariatric surgery in these patients will decrease the grade of steatosis, hepatic inflammation, and fibrosis. NAFLD per se is not an indication for bariatric surgery. Further research is urgently needed to determine (i) the benefit of bariatric surgery in NAFLD patients at high risk of developing liver cirrhosis (ii) the role of bariatric surgery in modulation of complications of NAFLD like diabetes and cardiovascular disease. The outcomes of the future research will determine whether bariatric surgery will be one of the recommended choice for treatment of the most progressive type of NAFLD.

Figures

Figure 1
Figure 1
Schematic figure illustrating the complex potential factors that associated with bariatric surgery that may have the potential role in the treatment of NAFLD.

References

    1. Adams LA, Angulo P. Treatment of non-alcoholic fatty liver disease. Postgraduate Medical Journal. 2006;82(967):315–322.
    1. Newburgh LH, Conn JW. A new interpretation of hyperglycemia in obese middle aged persons. The Journal of the American Medical Association. 1939;112:7–11.
    1. Zelman S. The liver in obesity. A.M.A. Archives of Internal Medicine. 1952;90:141–156.
    1. Ludwig J, Viggiano TR, McGill DB, Ott BJ. Nonalcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clinic Proceedings. 1980;55(7):434–438.
    1. Ahmed MH, Byrne CD. Non-alcoholic fatty liver disease. In: Byrne CD, Wild SH, editors. The Metabolic Syndrome. 2nd edition. Oxford, UK: Wiley-Blackwell; 2011. pp. 245–277.
    1. Angulo P. Medical progress: nonalcoholic fatty liver disease. The New England Journal of Medicine. 2002;346(16):1221–1231.
    1. Sass DA, Chang P, Chopra KB. Nonalcoholic fatty liver disease: a clinical review. Digestive Diseases and Sciences. 2005;50(1):171–180.
    1. Teli MR, James OFW, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology. 1995;22(6):1714–1719.
    1. Alba LM, Lindor K. Review article: non-alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics. 2003;17(8):977–986.
    1. Anstee QM, McPherson S, Day CP. How big a problem is non-alcoholic fatty liver disease? British Medical Journal. 2011;343(7816, article d3897)
    1. Edmison J, McCullough AJ. Pathogenesis of non-alcoholic steatohepatitis: human data. Clinics in Liver Disease. 2007;11(1):75–104.
    1. Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002;123(1):134–140.
    1. Day CP. Non-alcoholic fatty liver disease: current concepts and management strategies. Clinical Medicine. 2006;6(1):19–25.
    1. Oneta CM, Dufour JF. Non-alcoholic fatty liver disease: treatment options based on pathogenic considerations. Swiss Medical Weekly. 2002;132(35-36):493–505.
    1. Preiss D, Sattar N. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clinical Science. 2008;115(5-6):141–150.
    1. Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. The American Journal of Gastroenterology. 1999;94(4):1018–1022.
    1. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003;37(5):1202–1219.
    1. Setji TL, Holland ND, Sanders LL, Pereira KC, Diehl AM, Brown AJ. Nonalcoholic steatohepatitis and nonalcoholic fatty liver disease in young women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism. 2006;91(5):1741–1747.
    1. Stefan N, Kantartzis K, Häring HU. Causes and metabolic consequences of fatty liver. Endocrine Reviews. 2008;29(7):939–960.
    1. Silverman EM, Sapala JA, Appelman HD. Regression of hepatic steatosis in morbidly obese persons after gastric bypass. American Journal of Clinical Pathology. 1995;104(1):23–31.
    1. Clark JM, Alkhuraishi ARA, Solga SF, Alli P, Diehl AM, Magnuson TH. Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease. Obesity Research. 2005;13(7):1180–1186.
    1. Mattar SG, Velcu LM, Rabinovitz M, et al. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Annals of Surgery. 2005;242(4):610–620.
    1. Mottin CC, Moretto M, Padoin AV, et al. Histological behavior of hepatic steatosis in morbidly obese patients after weight loss induced by bariatric surgery. Obesity Surgery. 2005;15(6):788–793.
    1. Klein S, Mittendorfer B, Eagon JC, et al. Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. Gastroenterology. 2006;130(6):1564–1572.
    1. Barker KB, Palekar NA, Bowers SP, Goldberg JE, Pulcini JP, Harrison SA. Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery. The American Journal of Gastroenterology. 2006;101(2):368–373.
    1. Csendes A, Smok G, Burgos AM. Histological findings in the liver before and after gastric bypass. Obesity Surgery. 2006;16(5):607–611.
    1. de Almeida SR, Rocha PRS, Sanches MD, et al. Roux-en-Y gastric bypass improves the nonalcoholic steatohepatitis (NASH) of morbid obesity. Obesity Surgery. 2006;16(3):270–278.
    1. Furuya CK, Jr., de Oliveira CPMS, de Mello ES, et al. Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years. Journal of Gastroenterology and Hepatology. 2007;22(4):510–514.
    1. Liu X, Lazenby AJ, Clements RH, Jhala N, Abrams GA. Resolution of nonalcoholic steatohepatits after gastric bypass surgery. Obesity Surgery. 2007;17(4):486–492.
    1. Weiner RA. Surgical treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease. Digestive Diseases. 2010;28(1):274–279.
    1. Moretto M, Kupski C, da Silva VD, Padoin AV, Mottin CC. Effect of bariatric surgery on liver fibrosis. Obesity Surgery. 2012;22(7):1044–1049.
    1. Ranlov I, Hardt F. Regression of liver steatosis following gastroplasty or gastric bypass for morbid obesity. Digestion. 1990;47(4):208–214.
    1. Jaskiewicz K, Raczynska S, Rzepko R, Sledziński Z. Nonalcoholic fatty liver disease treated by gastroplasty. Digestive Diseases and Sciences. 2006;51(1):21–26.
    1. Stratopoulos C, Papakonstantinou A, Terzis I, et al. Changes in liver histology accompanying massive weight loss after gastroplasty for morbid obesity. Obesity Surgery. 2005;15(8):1154–1160.
    1. Dixon JB, Bhathal PS, Hughes NR, O’Brien PE. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology. 2004;39(6):1647–1654.
    1. Dixon JB, Bhathal PS, O’Brien PE. Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement. Obesity Surgery. 2006;16(10):1278–1286.
    1. Mathurin P, Hollebecque A, Arnalsteen L, et al. Prospective study of the long term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology. 2009;137(2):532–540.
    1. Kral JG, Thung SN, Biron S, et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery. 2004;135(1):48–58.
    1. Keshishian A, Zahriya K, Willes EB. Duodenal switch has no detrimental effects on hepatic function and improves hepatic steatohepatitis after 6 months. Obesity Surgery. 2005;15(10):1418–1423.
    1. Mottin CC, Moretto M, Padoin AV, et al. The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients. Obesity Surgery. 2004;14(5):635–637.
    1. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123(3):745–750.
    1. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002;123(5):1705–1725.
    1. Harrison SA. Liver disease in patients with diabetes mellitus. Journal of Clinical Gastroenterology. 2006;40(1):68–76.
    1. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37(4):917–923.
    1. McAvoy NC, Ferguson JW, Campbell IW, Hayes PC. Non-alcoholic fatty liver disease: natural history, pathogenesis and treatment. British Journal of Diabetes and Vascular Disease. 2006;6(6):251–260.
    1. Fan JG, Zhu J, Li XJ, et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. Journal of Hepatology. 2005;43(3):508–514.
    1. Bellentani S, Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD) Annals of Hepatology. 2009;8(supplement 1):S4–S8.
    1. Luyckx FH, Desaive C, Thiry A, et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. International Journal of Obesity. 1998;22(3):222–226.
    1. Tominaga K, Kurata JH, Chen YK, et al. Prevalence of fatty liver in Japanese children and relationship to obesity. An epidemiological ultrasonographic survey. Digestive Diseases and Sciences. 1995;40(9):2002–2009.
    1. Franzese A, Vajro P, Argenziano A, et al. Liver involvement in obese children: ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. Digestive Diseases and Sciences. 1997;42(7):1428–1432.
    1. Adams LA, Lymp JF, Sauver JS, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129(1):113–121.
    1. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone. Hepatology. 2003;38(4):1008–1017.
    1. Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Digestive Diseases. 2010;28(1):155–161.
    1. Hussein O, Grosovski M, Schlesinger S, Szvalb S, Assy N. Orlistat reverse fatty infiltration and improves hepatic fibrosis in obese patients with nonalcoholic steatohepatitis (NASH) Digestive Diseases and Sciences. 2007;52(10):2512–2519.
    1. Lingvay I, Raskin P, Szczepaniak LS. Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes. Journal of Diabetes and its Complications. 2007;21(3):137–142.
    1. Gomez EV, de Miranda AR, Oramas BG, et al. Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics. 2009;30(10):999–1009.
    1. Nobili V, Manco M, Devito R, et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology. 2008;48(1):119–128.
    1. Andersen T, Gluud C, Franzmann MB, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. Journal of Hepatology. 1991;12(2):224–229.
    1. Sjöström L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. The New England Journal of Medicine. 2004;351:2683–2693.
    1. Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. The New England Journal of Medicine. 2007;357(8):753–761.
    1. Sjöström L, Narbro K, Sjöström CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. The New England Journal of Medicine. 2007;357(8):741–752.
    1. Runkel N, Colombo-Benkmann M, Hüttl TP, Tigges H, Mann O, Sauerland S. Clinical practice guideline: bariatric surgery. Deutsches Arzteblatt. 2011;108(20):341–346.
    1. Brethauer SA, Chand B, Schauer PR. Risks and benefits of bariatric surgery: current evidence. Cleveland Clinic Journal of Medicine. 2006;73(11):993–1007.
    1. Ali MR, Fuller WD, Choi MP, Wolfe BM. Bariatric surgical outcomes. Surgical Clinics of North America. 2005;85(4):835–852.
    1. Salem L, Jensen CC, Flum DR. Are bariatric surgical outcomes worth their cost? A systematic review. Journal of the American College of Surgeons. 2005;200(2):270–278.
    1. Nguyen NT, Goldman C, Rosenquist CJ, et al. Laparoscopic versus open gastric bypass: a randomized study of outcomes, quality of life, and costs. Annals of Surgery. 2001;234(3):279–291.
    1. Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. The American Journal of Medicine. 2009;122(3):248.e5–256.e5.
    1. Karmali S, Schauer P, Birch D, Sharma AM, Sherman V. Laparoscopic sleeve gastrectomy: an innovative new tool in the battle against the obesity epidemic in Canada. Canadian Journal of Surgery. 2010;53(2):126–132.
    1. Schouten R, Wiryasaputra DC, van Dielen FMH, van Gemert WG, Greve JWM. Long-term results of bariatric restrictive procedures: a prospective study. Obesity Surgery. 2010;20(12):1617–1626.
    1. Rabl C, Campos GM. The impact of bariatric surgery on nonalcoholic steatohepatitis. Seminars in Liver Disease. 2012;32:80–91.
    1. O'Brien PE, Dixon JB, Laurie C, et al. Treatment of mild to moderate obesity with laparoscopic adjustable gastric banding or an intensive medical program: a randomised trial. Annals of Internal Medicine. 2006;144:625–633.
    1. To VT, Hüttl TP, Lang R, Piotrowski K, Parhofer KG. Changes in body weight, glucose homeostasis, lipid profiles, and metabolic syndrome after restrictive bariatric surgery. Experimental and Clinical Endocrinology & Diabetes. 2012;120(9):547–552.
    1. Saboya C, Arasaki CH, Matos D, Lopes-Filho GJ. Relationship between the preoperative body mass index and the resolution of metabolic syndrome following Roux-en-Y gastric bypass. Metabolic Syndrome and Related Disorders. 2012;10(4):292–296.
    1. Júnior FCM, Júnior WS, Filho NS, et al. Effects of weight loss induced by bariatric surgery on the prevalence of metabolic syndrome. Arquivos Brasileiros de Cardiologia. 2009;92(6):418–422, 435–439, 452–456.
    1. Inabnet WB, III, Winegar DA, Sherif B, Sarr MG. Early outcomes of bariatric surgery in patients with metabolic syndrome: an analysis of the bariatric outcomes longitudinal database. Journal of the American College of Surgeons. 2012;214(4):550–557.
    1. Bretón JO, García B, Benito P, Gimeno S, García R, López P. Effect of gastric bypass on the metabolic syndrome and on cardiovascular risk. Nutrición Hospitalaria. 2010;25(1):67–71.
    1. Pontiroli AE, Laneri M, Veronelli A, et al. Biliary pancreatic diversion and laparoscopic adjustable gastric banding in morbid obesity: their long-term effects on metabolic syndrome and on cardiovascular parameters. Cardiovascular Diabetology. 2009;8, article 37
    1. Batsis JA, Romero-Corral A, Collazo-Clavell ML, Sarr MG, Somers VK, Lopez-Jimenez F. Effect of bariatric surgery on the metabolic syndrome: a population-based, long-term controlled study. Mayo Clinic Proceedings. 2008;83(8):897–906.
    1. Nugent C, Bai C, Elariny H, et al. Metabolic syndrome after laparoscopic bariatric surgery. Obesity Surgery. 2008;18(10):1278–1286.
    1. Madan AK, Orth W, Ternovits CA, Tichansky DS. Metabolic syndrome: yet another co-morbidity gastric bypass helps cure. Surgery for Obesity and Related Diseases. 2006;2(1):48–51.
    1. Lee WJ, Huang MT, Wang W, Lin CM, Chen TC, Lai IR. Effects of obesity surgery on the metabolic syndrome. Archives of Surgery. 2004;139(10):1088–1092.
    1. Alexandrides TK, Skroubis G, Kalfarentzos F. Resolution of diabetes mellitus and metabolic syndrome following Roux-en-Y gastric bypass and a variant of biliopancreatic diversion in patients with morbid obesity. Obesity Surgery. 2007;17(2):176–184.
    1. Skroubis G, Anesidis S, Kehagias I, Mead N, Vagenas K, Kalfarentzos F. Roux-en-Y gastric bypass versus a variant of biliopancreatic diversion in a non-superobese population: prospective comparison of the efficacy and the incidence of metabolic deficiencies. Obesity Surgery. 2006;16(4):488–495.
    1. Angrisani L, Lorenzo M, Borrelli V. Laparoscopic adjustable gastric banding versus Roux-en-Y gastric bypass: 5-year results of a prospective randomized trial. Surgery for Obesity and Related Diseases. 2007;3(2):127–132.
    1. Greenway SE, Greenway FL, III, Klein S. Effects of obesity surgery on non-insulin-dependent diabetes mellitus. Archives of Surgery. 2002;137(10):1109–1117.
    1. Carson JL, Ruddy ME, Duff AE, Holmes NJ, Cody RP, Brolin RE. The effect of gastric bypass surgery on hypertension in morbidly obese patients. Archives of Internal Medicine. 1994;154(2):193–200.
    1. Nguyen NT, Varela E, Sabio A, Tran CL, Stamos M, Wilson SE. Resolution of hyperlipidemia after laparoscopic Roux en Y gastric bypass. Journal of the American College of Surgeons. 2006;203(1):24–29.
    1. Brolin RE, Bradley LJ, Wilson AC, Cody RP. Lipid risk profile and weight stability after gastric resective operations for morbid obesity. Journal of Gastrointestinal Surgery. 2000;4(5):464–469.
    1. Ahmed MH, Byrne CD. Ezetimibe as a potential treatment for non-alcoholic fatty liver disease: is the intestine a modulator of hepatic insulin sensitivity and hepatic fat accumulation? Drug Discovery Today. 2010;15(15-16):590–595.
    1. Byrne CD, Olufad R, Bruce KD, Cagampang FR, Ahmed MH. Metabolic disturbances in non-alcoholic fatty liver disease. Clinical Science. 2009;116(7):539–564.
    1. Ahmed MH, Byrne CD. Current treatment of non-alcoholic fatty liver disease. Diabetes, Obesity and Metabolism. 2009;11(3):188–195.
    1. Cnop M, Havel PJ, Utzschneider KM, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia. 2003;46(4):459–469.
    1. Hivert MF, Sullivan LM, Fox CS, et al. Associations of adiponectin, resistin, and tumor necrosis factor-α with insulin resistance. Journal of Clinical Endocrinology and Metabolism. 2008;93(8):3165–3172.
    1. Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Annals of Surgery. 1995;222(3):339–350.
    1. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. The Journal of the American Medical Association. 2004;292(14):1724–1737.
    1. Holdstock C, Lind L, Eden Engstrom B, et al. CRP reduction following gastric bypass surgery is most pronounced in insulin-sensitive subjects. International Journal of Obesity. 2005;29(10):1275–1280.
    1. Vilarrasa N, Vendrell J, Sánchez-Santos R, et al. Effect of weight loss induced by gastric bypass on proinflammatory interleukin-18, soluble tumour necrosis factor-α receptors, C-reactive protein and adiponectin in morbidly obese patients. Clinical Endocrinology. 2007;67(5):679–686.
    1. Drucker DJ. The role of gut hormones in glucose homeostasis. Journal of Clinical Investigation. 2007;117(1):24–32.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner